

# Special Issue

## Genitourinary Malignancies

### Message from the Guest Editor

Genitourinary malignancies, including prostate, bladder, kidney, and testicular cancers, are at the forefront of innovation, with a continuous influx of novel therapeutics reshaping treatment paradigms. Although the pipeline of new therapeutics continues to evolve, achieving the ultimate goal of personalized medicine proves challenging. The scarcity of reliable biomarkers predicting responses or toxicities to cancer treatments has prompted the development of several drug combinations which ultimately improve outcomes. Nevertheless, the introduction of these combinations, coupled with numerous recent changes in frontline treatments, has intensified the complexity of treatment selection and sequencing, as well as the optimization of toxicity management and quality of life. This Special Issue welcomes manuscripts addressing the unknowns surrounding treatment optimization, the development of predictive markers, the refinement of therapy sequencing, and the strategies to improve and prevent drug toxicity as well as patients' quality of life.

---

### Guest Editor

Dr. Dominick Bosse

Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada

---

### Deadline for manuscript submissions

closed (31 July 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/191141](https://mdpi.com/si/191141)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)